154 related articles for article (PubMed ID: 28177767)
1. PRPS1 silencing reverses cisplatin resistance in human breast cancer cells.
He M; Chao L; You YP
Biochem Cell Biol; 2017 Jun; 95(3):385-393. PubMed ID: 28177767
[TBL] [Abstract][Full Text] [Related]
2. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
3. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells.
Qiu Z; Guo W; Wang Q; Chen Z; Huang S; Zhao F; Yao M; Zhao Y; He X
Gastroenterology; 2015 Nov; 149(6):1587-1598.e11. PubMed ID: 26248089
[TBL] [Abstract][Full Text] [Related]
5. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
6. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
7. Cell-Cycle-Dependent Phosphorylation of PRPS1 Fuels Nucleotide Synthesis and Promotes Tumorigenesis.
Jing X; Wang XJ; Zhang T; Zhu W; Fang Y; Wu H; Liu X; Ma D; Ji X; Jiang Y; Liu K; Chen X; Shi Y; Zhang Y; Shi M; Qiu W; Zhao R
Cancer Res; 2019 Sep; 79(18):4650-4664. PubMed ID: 31253668
[TBL] [Abstract][Full Text] [Related]
8. Down-Regulation of Phosphoribosyl Pyrophosphate Synthetase 1 Inhibits Neuroblastoma Cell Proliferation.
Li J; Ye J; Zhu S; Cui H
Cells; 2019 Aug; 8(9):. PubMed ID: 31443513
[TBL] [Abstract][Full Text] [Related]
9. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.
Wei L; Wang XW; Sun JJ; Lv LY; Xie L; Song XR
Asian Pac J Cancer Prev; 2015; 16(3):875-80. PubMed ID: 25735376
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
13. Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.
Shen X; Zheng JY; Shi H; Zhang Z; Wang WZ
Am J Med Sci; 2012 Jul; 344(1):52-8. PubMed ID: 22261621
[TBL] [Abstract][Full Text] [Related]
14. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ.
Yang W; Yang X; Wang X; Gu J; Zhou D; Wang Y; Yin B; Guo J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):4921-4932. PubMed ID: 31245927
[TBL] [Abstract][Full Text] [Related]
15. CA916798 regulates multidrug resistance of lung cancer cells.
Wang HJ; Yang HP; Zhou XD; Dai XT; Chen YF; Xiong W
Asian Pac J Cancer Prev; 2011; 12(12):3403-8. PubMed ID: 22471488
[TBL] [Abstract][Full Text] [Related]
16. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
17. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
[TBL] [Abstract][Full Text] [Related]
18. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
20. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
